Katharine Yen
Founder & Chief Executive Officer Auron Therapeutics
Seminars
Tuesday 27th October 2026
Targeting KAT2A/B with an Oral Heterobifunctional Degrader for Heme Malignancies & Inflammatory Diseases
4:30 pm
- AUTX-703 is in phase 1 development for hematological malignancies
- AUTX-163 for inflammatory diseases
